Trade Akero Therapeutics Inc - AKRO CFD

Add to favourite

55.94

3.76%

0.20

Low: 54.65

High: 56.92

Market Trading Hours* (UTC) Open now
Closes on Thursday at 21:00

Mon - Fri: 14:30 - 21:00

Summary
Historical Data

Trading сonditions

Spread

0.20

Long position overnight fee

-0.023512%

Short position overnight fee

0.00129%

Overnight fee time

22:00 (UTC)

Min traded quantity

Currency

USD

Margin

5.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	53.95
Open	55.09
1-Year Change	478.07%
Day's Range	54.65 - 56.92

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Jan 29, 2025	53.95	2.00	3.85%	51.95	55.57	51.65
Jan 28, 2025	51.42	-2.53	-4.69%	53.95	57.38	49.28
Jan 27, 2025	51.65	-2.90	-5.32%	54.55	58.23	48.35
Jan 24, 2025	26.13	0.34	1.32%	25.79	26.29	25.59
Jan 23, 2025	26.11	1.45	5.88%	24.66	26.14	24.55
Jan 22, 2025	24.95	-0.62	-2.42%	25.57	25.71	24.67
Jan 21, 2025	25.55	0.46	1.83%	25.09	26.13	25.09
Jan 17, 2025	25.06	0.78	3.21%	24.28	25.49	23.57
Jan 16, 2025	23.95	2.00	9.11%	21.95	24.27	21.95
Jan 15, 2025	22.26	0.11	0.50%	22.15	22.65	21.78
Jan 14, 2025	21.81	-0.84	-3.71%	22.65	22.79	21.28
Jan 13, 2025	22.57	-1.84	-7.54%	24.41	24.41	22.25
Jan 10, 2025	24.77	-0.61	-2.40%	25.38	25.88	24.37
Jan 8, 2025	26.09	-0.19	-0.72%	26.28	26.59	25.83
Jan 7, 2025	26.52	-1.07	-3.88%	27.59	28.02	26.19
Jan 6, 2025	27.54	-0.41	-1.47%	27.95	28.78	27.52
Jan 3, 2025	28.14	0.64	2.33%	27.50	28.61	27.50
Jan 2, 2025	28.02	0.05	0.18%	27.97	28.28	27.49
Dec 31, 2024	27.75	-0.53	-1.87%	28.28	28.28	27.45
Dec 30, 2024	27.90	0.16	0.58%	27.74	27.96	27.43

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

1:1
2:1
3:1
5:1
10:1
20:1

Leverage

20:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Akero Therapeutics Inc

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.